Methods of making active antibodies from biological fluids
The present invention provides a method of making an antibody by identifying a circulating antibody with activity from a subject comprising i) subjecting biological fluid selected from the group consisting of blood, plasma and serum and combinations thereof from the subject to one or more rounds of affinity chromatography to purify the circulating antibody; ii) optionally further subjecting the circulating antibody to isoelectric focusing to purify the circulating antibody based on charge; iii) testing the purified circulating antibody for activity; iv) digesting the purified circulating antibody from parts i) or ii) to create an antibody fragment; v) subjecting the antibody fragment to mass spectrometry to generate a mass assignment and a deduced amino acid sequence of the antibody fragment; vi) comparing the deduced amino acid sequence with an amino acid sequence of an antibody generated from the subject's B-cells to identify an antibody sequence that matches the deduced amino acid sequence; vii) generating an antibody comprising light chain and heavy chain CDR sequences of the B-cell antibody that matches the deducted amino acid sequence of party vi); and viii) testing the antibody of part vii) for activity.
1. A method of making an antibody by identifying a circulating antibody with activity from a subject comprising:
i) subjecting biological fluid selected from the group consisting of blood, plasma and serum and combinations thereof from the subject to one or more rounds of affinity chromatography to purify the circulating antibody;
ii) optionally further subjecting the circulating antibody to isoelectric focusing to purify the circulating antibody based on charge;
iii) testing the purified circulating antibody for activity;
iv) digesting the purified circulating antibody from parts i) or ii) to create an antibody fragment;
v) subjecting the antibody fragment to mass spectrometry to generate a mass assignment and a deduced amino acid sequence of the antibody fragment;
vi) comparing the deduced amino acid sequence with an amino acid sequence of an antibody generated from the subject's B-cells to identify an antibody sequence that matches the deduced amino acid sequence;
vii) generating an antibody comprising light chain and heavy chain CDR sequences of the B-cell antibody that matches the deduced amino acid sequence of part vi); and
viii) testing the antibody of part vii) for activity;
wherein the circulating antibody with activity binds an HIV antigen selected from the group consisting of gp120, p24, gp41, p31, p17, p55, RT, rev, nef, vpu, and tat; and
wherein the B-cells comprise bone marrow cells exhibiting a long or short-lived phenotype, wherein the B-cells have a phenotype that is CD38hi, CD19+ or CD19−, and CD138+ or CD138−.
2. The method of claim 1 , wherein the circulating antibody with activity binds free gp120.
3. The method of claim 1 , wherein the circulating antibody with activity is an IgG antibody.
4. The method of claim 3 , wherein the circulating antibody with activity is an IgG1 antibody.
5. The method of claim 1 , wherein the circulating antibody with activity has a kappa light chain.
6. The method of claim 1 , wherein the circulating antibody has a lambda light chain.
7. The method of claim 1 , wherein the B-cells are from blood, lymph node and bone marrow.
8. The method of claim 7 , wherein the B-cells comprise plasmablasts, plasma cells, and memory B cells.
9. The method of claim 1 , wherein the B-cells are analyzed by single cell PCR and/or deep sequencing to generate heavy chain and light chain amino acid antibody sequences.
10. The method of claim 1 , wherein the B-cells comprise bone marrow cells having the phenotype IgA−, IgM−, IgD−, CD19+(or CD19−), CD20−, CD27+, CD38hi and CD138−(or CD138+).
11. The method of claim 1 , wherein the circulating antibody binds a gp120 epitope selected from the group consisting of a CD4 binding site, a CD4 induced epitope, and a V3 epitope.
12. The method of claim 1 , wherein the subject exhibits a neutralizing polyclonal antibody response that comprises circulating antibodies against gp120 epitopes comprising a CD4 binding site, a CD4 induced epitope, and a V3 epitope.
13. The method of claim 1 , wherein the circulating antibody comprises less than 1% of the circulating IgG in the subject.
14. The method of claim 1 , wherein the affinity chromatography comprises purifying circulating plasma IgG antibody using protein A.
15. The method of claim 1 , wherein the affinity chromatography comprises purifying circulating antibody using an antigen.
16. The method of claim 1 , wherein the affinity chromatography comprises purifying circulating IgG1 kappa chain antibodies.
17. The method of claim 1 , wherein the affinity chromatography comprises purifying circulating IgG1 lambda chain antibodies.
18. The method of claim 1 , wherein the purified circulating antibody of parts i) and/or ii) is tested in a binding and/or functional assay prior to subjecting the antibody fragments to mass spectrometry.
19. A method of identifying a circulating antibody with activity from a subject comprising
i) subjecting biological fluid selected from the group consisting of blood, plasma and serum and combinations thereof from the subject to one or more rounds of affinity chromatography to purify the circulating antibody;
ii) optionally further subjecting the circulating antibody to isoelectric focusing to purify the circulating antibody based on charge;
iii) testing the purified circulating antibody for activity;
iv) digesting the purified circulating antibody from parts i) or ii) to create an antibody fragment;
v) subjecting the antibody fragment to mass spectrometry to generate a mass assignment and a deduced amino acid sequence of the antibody fragment; and
vi) comparing the deduced amino acid sequence with an amino acid sequence of an antibody generated from the subject's B-cells to identify an antibody sequence that matches the deduced amino acid sequence;
wherein the circulating antibody with activity binds an HIV antigen selected from the group consisting of gp120, p24, gp41, p31, p17, p55, RT, rev, nef, vpu, and tat; and
wherein the B-cells comprise bone marrow cells exhibiting a long or short-lived phenotype, wherein the B-cells have a phenotype that is CD38hi, CD19+ or CD19−, and CD138+ or CD138−.
20. The method of claim 19 , wherein the circulating antibody with activity binds free gp120.
21. The method of claim 19 , wherein the B-cells are analyzed by single cell PCR and/or deep sequencing to generate heavy chain and light chain amino acid antibody sequences.
22. The method of claim 19 , wherein the B-cells comprise circulating plasmablasts having the phenotype IgA−, IgM−, IgD−, CD19+, CD20−, CD27+, and CD38hi.
23. The method of claim 19 , wherein the B-cells comprise bone marrow cells having the phenotype IgA-, IgM-, IgD-, CD19+ or CD19−, CD20−, CD27+, CD38hi and CD138+ or CD138−.
24. The method of claim 19 , wherein the circulating antibody binds a gp120 epitope selected from the group consisting of a CD4 binding site, a CD4 induced epitope, and a V3 epitope.
25. The method of claim 19 , wherein the subject exhibits a neutralizing polyclonal antibody response that comprises circulating antibodies against gp120 epitopes comprising a CD4 binding site, a CD4 induced epitope, and a V3 epitope.
26. The method of claim 19 , wherein the affinity chromatography comprises purifying circulating IgG antibody using protein A.
27. The method of claim 19 , wherein the affinity chromatography comprises purifying circulating antibody using an antigen.
28. The method of claim 19 , wherein the affinity chromatography comprises purifying circulating IgG1 kappa chain antibodies.
29. The method of claim 19 , wherein the affinity chromatography comprises purifying circulating IgG1 lambda chain antibodies.
30. The method of claim 19 , wherein the purified circulating antibody of parts i) and/or ii) is tested in a binding and/or functional assay prior to subjecting the antibody fragments to mass spectrometry.